Breakthrough Gene Therapy Thought to Be an Effective Treatment for Some Kinds of Cancers Just Turned Deadly
Immunotherapy represents a whole new approach for combating several types of human cancers. The tactic involves scientists genetically reprogramming the cells of a person’s immune system to target and attack malignancies. Immunotherapy is now considered the “fifth pillar” of cancer treatments, rapidly evolving into a more promising tool for battling cancer than standard radiation and chemotherapeutic treatments.
Although there are many different immunotherapies in development and practice, chimeric antigen receptor T-cells (CAR-T) therapy has shown the most promise to date. Indeed, CAR-T therapy is the first anti-cancer gene therapy to be approved by the United States Food and Drug Administration (FDA) for use against advanced adult lymphomas and childhood acute lymphoblastic leukemia. Unfortunately, just recently, a patient given CAR-T therapy for aggressive leukemia died as result of the treatment.
Our DNA has the power to unlock endless stories of who we are and where we came from, but what if we could change it forever? 44-year old Brian Madeux may be among the first to know: Last month, Madeux was the first individual to receive in-body gene editing, in an attempt to treat his Hunter Syndrome, a rare metabolic condition tied to a genetic mutation.
To carry out this groundbreaking therapy, scientists flooded Madeux’s body via IV with billions of copies of a corrective gene, as well as with a gene editor known as zinc finger nuclease (ZFN), intended to insert the new gene into his DNA.